<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Sherlock Biosciences — Prospect Detail</title>
  <link rel="stylesheet" href="styles.css">
</head>
<body>
<header class="site-header"><h1>Prospect Detail</h1></header>
<div class="container">
  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>
  <div class="detail-header">
    <span class="badge health" style="font-size:.8rem;">Diagnostics</span>
    <h1>133. Sherlock Biosciences</h1>
    <p class="meta">First FDA-Cleared CRISPR Diagnostic Technology</p>
  </div>
  <div class="section"><h3>1. Startup Name</h3><p><strong>Sherlock Biosciences</strong></p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Tell me more about this company's origin story...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section"><h3>2. Founder Contact</h3><p><strong>James Collins & David Walt</strong></p><p>Wyss Institute / Broad Institute</p><p>Dr. Collins is a pioneer in synthetic biology; Dr. Walt invented the fiber optic bead array technology behind Illumina; both are Wyss Core Faculty</p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Research the founder's background and credentials...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section"><h3>3. Product Overview</h3><p>Sherlock Biosciences develops next-generation molecular diagnostics using CRISPR-based SHERLOCK technology and synthetic biology-based INSPECTR platform. The company achieved a historic milestone as the first to receive FDA authorization for a CRISPR-based diagnostic test. Their technology enables highly sensitive, specific, and affordable diagnostic tests that can be deployed at point-of-care settings without expensive laboratory equipment.</p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="What competitors does this product face?">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section"><h3>4. Funding Stage</h3><p><strong>Series B — $80M</strong> — Advancing commercial deployment of FDA-cleared CRISPR diagnostics platform.</p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="What's the typical next funding milestone?">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section"><h3>5. How I Found the Company</h3><p>Discovered through Wyss Institute portfolio and coverage of FDA's first CRISPR diagnostic authorization.</p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Find more recent news about this company...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="strengths-weaknesses">
    <div class="section"><h3>Strengths</h3><ul><li><strong>Regulatory first-mover:</strong> First FDA-authorized CRISPR diagnostic creates significant competitive moat.</li><li><strong>Legendary founders:</strong> James Collins and David Walt are giants in synthetic biology and diagnostics.</li><li><strong>Platform versatility:</strong> SHERLOCK and INSPECTR platforms can address multiple disease areas.</li></ul>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Validate these strengths with market data...">
        <button>Ask AI</button>
      </div>
    </div>
    </div>
    <div class="section"><h3>Weaknesses</h3><ul><li><strong>Competitive landscape:</strong> Mammoth Biosciences and other CRISPR diagnostics players are well-funded.</li><li><strong>Commercial scaling:</strong> Moving from FDA approval to widespread clinical adoption takes time.</li></ul>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="What other risks should I consider?">
        <button>Ask AI</button>
      </div>
    </div>
    </div>
  </div>
  <div class="section"><h3>7. Five Questions for the Team</h3><ol class="questions-list"><li>What disease areas are you prioritizing for your next FDA submissions?</li><li>How does your cost-per-test compare to traditional PCR and other molecular diagnostics?</li><li>What is your go-to-market strategy — direct to health systems, reference labs, or partnerships?</li><li>How are SHERLOCK and INSPECTR platforms differentiated for different use cases?</li><li>What is your IP position relative to other CRISPR diagnostics companies?</li></ol>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Generate additional due diligence questions...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section email-draft">
    <h3>8. Draft Outreach Email</h3>
    <div class="email-box">
      <p><strong>Subject:</strong> Harvard Undergraduate Capital Partners — Celebrating Sherlock's FDA CRISPR Milestone</p>
      <p>Dear Sherlock Biosciences Team,</p>
      <p>I'm reaching out from <strong>Harvard Undergraduate Capital Partners (HUCP)</strong>, a student-run investment group at Harvard focused on early-stage ventures led by Harvard-affiliated founders.</p>
      <p>We've been following Sherlock Biosciences with great interest, particularly the historic achievement of becoming the first company to receive FDA authorization for a CRISPR-based diagnostic. The work pioneered by Dr. Collins and Dr. Walt at the Wyss Institute represents exactly the kind of transformative Harvard innovation we seek to support.</p>
      <p>Would anyone on the team be open to a brief conversation about Sherlock's journey from Wyss Institute research to commercial diagnostics? We'd love to learn from your experience and explore how HUCP might contribute to your mission.</p>
      <p>Thank you for your time.</p>
      <p>Best,<br>[Your Name]<br>Harvard Undergraduate Capital Partners</p>
    </div>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Personalize this email with more specific details...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>
</div>
<script src="script.js?v=4"></script>
</body>
</html>
